A meeting of the National Drug Scheduling Advisory Committee (NDSAC) was held on December 6, 2021 with the following interim recommendations made:

• Brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older be granted Schedule III status, subject to the removal from the Prescription Drug List (PDL)
• Brimonidine or its salts, except when sold as brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older will remain in Schedule I (as per the Prescription Drug List)

Any objections to these interim recommendations must be received by the NAPRA office by end of day January 13, 2022. Questions or comments should be directed to the NDSAC Secretariat via email at ndsac@napra.ca.